Thus far, only Oct3/4, Nanog and CD133 were reported to be candidates for CSC-specific markers in bone and soft tissue sarcoma (Gibbs et al, 2005; Tirino et al, 2008). The gene discussed is NANOG; the disease is short stature-onychodysplasia-facial dysmorphism-hypotrichosis syndrome.